Clinical trial
Merging Strategy That Uses Gut Microbiome Profiling and Targeted Modulation to Improve CAR-T Cell Therapy Outcomes, Predict Responses, and Reduce Toxicity
NCT07871747 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Merging Strategy That Uses Gut Microbiome Profiling and Targeted Modulation to Improve CAR-T Cell Therapy Outcomes, Predict Responses, and Reduce Toxicity
- Lead sponsor
- University of Chicago
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- February 23, 2027
- Completion date
- September 10, 2030
- Enrollment
- 32 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.